Sanofi Exceeds Q2 Earnings Expectations Driven by Strong Dupixent Sales
Sanofi (SNY) reported second-quarter results that exceeded both revenue and profit expectations, primarily driven by a significant increase in sales of its blockbuster drug, Dupixent. The medication for eczema and asthma saw nearly 38% growth year-over-year, reaching over €5.2 billion in sales. Despite the strong performance from Dupixent, concerns persist regarding Sanofi's reliance on this single product to drive overall revenue. Other segments of its portfolio continue to underperform or show slower growth compared to expectations. This raises questions about long-term sustainability and diversification within the company’s drug offerings.
Tickers: $SNY